A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Di Giacomo, A.M.; Schenker, M.; Medioni, J.; Mandziuk, S.; Majem, M.; Gravis, G.; Cornfeld, M.; Ranganathan, S.; Lou, S.; Csoszi, T.

doi:10.1016/j.esmoop.2024.102387

Cited by 4 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This therapy is the first PD-1 mAb developed to treat Merkel cell carcinoma (MCC) 2 , 22 . A phase II clinical trial (NCT03679767) 23 has recently published findings on the efficacy of retifanlimab in the treatment of solid tumors. The results have indicated significant anti-tumor activity in melanoma, non-small-cell lung cancer (NSCLC), and renal cell carcinoma (RCC).…”

Section: Traditional Icismentioning

confidence: 99%

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Kong,

Zhang,

Chen

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

Over the past two decades, immunotherapies have increasingly been considered as first-line treatments for most cancers. One such treatment is immune checkpoint blockade (ICB), which has demonstrated promising results against various solid tumors in clinical trials. Monoclonal antibodies (mAbs) are currently available as immune checkpoint inhibitors (ICIs). These ICIs target specific immune checkpoints, including cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1). Clinical trial results strongly support the feasibility of this immunotherapeutic approach. However, a substantial proportion of patients with cancer develop resistance or tolerance to treatment, owing to tumor immune evasion mechanisms that counteract the host immune response. Consequently, substantial research focus has been aimed at identifying additional ICIs or synergistic inhibitory receptors to enhance the effectiveness of anti-PD-1, anti-programmed cell death ligand 1 (anti-PD-L1), and anti-CTLA-4 treatments. Recently, several immune checkpoint molecular targets have been identified, such as T cell immunoreceptor with Ig and ITIM domains (TIGIT), mucin domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), V-domain immunoglobulin suppressor of T cell activation (VISTA), B and T lymphocyte attenuator (BTLA), and signal-regulatory protein α (SIRPα). Functional mAbs targeting these molecules are under development. CTLA-4, PD-1/PD-L1, and other recently discovered immune checkpoint proteins with distinct structures are at the forefront of research. This review discusses these structures, as well as clinical progress in mAbs targeting these immune checkpoint molecules and their potential applications.

show abstract

Section: Traditional Icismentioning

confidence: 99%